0
There is no goods in the shopping cart !
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z 0-9
Your Position: Home > Immune Checkpoint Proteins > OX40 Ligand > OXL-H52Q8

Human OX40 Ligand / TNFSF4 Protein, His Tag (active trimer) (MALS verified)

  • Synonym
    OX40L,TNFSF4,CD252,Glycoprotein Gp34,TXGP1,CD134 ligand,CD134L
  • Source
    Human OX40 Ligand, His Tag (active trimer) (MALS verified) (OXL-H52Q8) is expressed from human 293 cells (HEK293). It contains AA Gln 51 - Leu 183 (Accession # NP_003317).
    Predicted N-terminus: His
  • Molecular Characterization
    Online(Gln 51 -  Leu 183) NP_003317

    This protein carries a polyhistidine tag at the N-terminus.

    The protein has a calculated MW of 16.9 kDa. The protein migrates as 25-30 kDa under reducing (R) condition (SDS-PAGE) due to glycosylation.

  • Endotoxin
    Less than 1.0 EU per μg by the LAL method.
  • Purity

    >90% as determined by SDS-PAGE.

    >95% as determined by SEC-MALS.

  • Formulation

    Lyophilized from 0.22 μm filtered solution in PBS, pH7.4. Normally trehalose is added as protectant before lyophilization.

    Contact us for customized product form or formulation.

  • Reconstitution

    Please see Certificate of Analysis for specific instructions.

    For best performance, we strongly recommend you to follow the reconstitution protocol provided in the CoA.

  • Storage

    For long term storage, the product should be stored at lyophilized state at -20°C or lower.

    Please avoid repeated freeze-thaw cycles.

    This product is stable after storage at:

    1. -20°C to -70°C for 12 months in lyophilized state;
    2. -70°C for 3 months under sterile conditions after reconstitution.
SDS-PAGE
Human OX40 Ligand, His Tag (active trimer) (MALS verified) (Cat. No. OXL-H52Q8) SDS-PAGE gel

Human OX40 Ligand, His Tag (active trimer) (MALS verified) on SDS-PAGE under reducing (R) condition. The gel was stained overnight with Coomassie Blue. The purity of the protein is greater than 90%.

SEC-MALS
Human OX40 Ligand, His Tag (active trimer) (MALS verified) (Cat. No. ) MALS images

The purity of Human OX40 Ligand, His Tag (active trimer) (MALS verified) (Cat. No. OXL-H52Q8) was more than 95% in HP-SEC, and around 60-80 kDa verified by SEC-MALS.

Bioactivity-ELISA
Human OX40 Ligand, His Tag (active trimer) (MALS verified)Human OX40 Ligand, His Tag (active trimer) (MALS verified) (Cat. No. OXL-H52Q8) ELISA bioactivity

Immobilized Biotinylated Human OX40, Fc,Avitag (Cat. No. OX0-H82F7) at 2 μg/mL (100 μL/well) on streptavidin precoated (0.5 μg/well) plate, can bind Human OX40 Ligand, His Tag (active trimer) (MALS verified) (Cat. No. OXL-H52Q8) with a linear range of 5-39 ng/mL (QC tested).

Human OX40 Ligand, His Tag (active trimer) (MALS verified)Human OX40 Ligand, His Tag (active trimer) (MALS verified) (Cat. No. OXL-H52Q8) ELISA bioactivity

Immobilized Human OX40 Ligand, His Tag (active trimer) (MALS verified) (Cat. No. OXL-H52Q8) at 2 μg/mL (100 μL/well) can bind Biotinylated Human OX40, Fc,Avitag (Cat. No. OX0-H82F7) with a linear range of 10-78 ng/mL (Routinely tested).

  • Background
    Tumor necrosis factor ligand superfamily member 4 (TNFSF4) is also known as glycoprotein Gp34, OX40 ligand (OX40L), TAX transcriptionally-activated glycoprotein 1 and CD252, which belongs to the tumor necrosis factor family. TNFSF4 is the ligand for CD134 and is expressed on such cells as DC2s (a subtype of dendritic cells) enabling amplification of Th2 cell differentiation. The interaction of TNFSF4-TNFSF4 is involved in the pathogenesis of multiple autoimmune and inflammatory diseases such as systemic lupus erythematosus (SLE), carotid artery disease and cancer. Furthermore, similar to other TNF superfamily members, membrane-bound OX40 Ligand (TNFSF4) exists as a homotrimer. Human TNFSF4 shares 46% amino acid sequence identity with its mouse counterpart.
  • References
  • Please contact us via TechSupport@acrobiosystems.com if you have any question on this product.

Comments (0)

Order Details

Price(USD) : $380.00

Price(USD) : $2600.00

Promotion & Exhibitions

  • PEGS Boston 2019
  • PepTalk 2019

Drug Development Status

  • Number of Launched Drugs:0 Details
  • Number of Drugs in Clinical Trials:3 Details
  • Latest Research Phase:Phase ?

Datasheet & Documentation

Contact Us

+1  800-810-0816 (US)
+86 400-682-2521 (AP)

Questions & Comments

This web search service is supported by Google Inc.

totop